

EXHIBIT 1



**Christian Tregillis, CPA/ABV
Managing Director, LECG**

2049 Century Park East, Suite 2300
Los Angeles, CA 90067
United States of America

Phone: 310.557.9913
Fax: 310.300.2244
Email: ctregillis@lecg.com

SUMMARY

Christian Tregillis is a managing director in the Century City office of LECG, where he leads the local Damages and Intellectual Property practice and also works on forensic accounting investigations. In these roles he analyzes financial, accounting, statistical, economic and market issues, primarily in regards to disputes and valuations. He has participated in mediations and has testified in deposition, hearings, arbitration and at trial in both state and federal courts.

Mr. Tregillis has worked on over 400 matters in his 18 years of financial consulting and investigations, including 11 years at Big Four accounting firms in their financial consulting groups. Most recently he led the Forensic Accounting & Litigation Consulting practice in the Western US and was the national leader of Kroll's Intellectual Property Services practice. Prior to that he was a partner in the Financial Advisory Services practice at Deloitte & Touche in Los Angeles, where he led the office's Commercial Litigation consulting group and Intellectual Asset Management practice.

Mr. Tregillis currently serves as the chair of the Economic Damages Task Force of the American Institute of Certified Public Accountants (AICPA), on the AICPA's Forensic & Litigation Services Committee, as the chair of the Economic Damages Section of the California Society of Certified Public Accountants (CalCPA), and on the Steering Committee of CalCPA's Litigation Sections. He served from 2003 to 2007 on the Board of Trustees of the Center for Law in the Public Interest and was the Center's Chief Financial Officer.

SELECT ENGAGEMENTS

- **States v. pharmaceutical company.** The states' attorneys general have investigated and continue to investigate defendant related to the prices charged to Medicaid and other agencies for various drugs, particularly in comparison to costs and other figures that were to be a part of the pricing formulae. Mr. Tregillis has led the team's investigation of the pricing and potential damages to individual states, including development of a database of transactions over several years that includes millions of reimbursements.

LECG

- **Shareholders v. blood testing company.** After a DOJ/OIG investigation into the company's billing practices for a panel of blood tests, where prices were different depending on the paying party, the company agreed to a settlement with the government, which led to a large decline in the stock price. Mr. Tregillis led the team investigating the nature of the investigation, when information became available that would have caused for disclosure or accrual under SFAS 5, and damages issues. The matter settled before testimony was given.
- **Dental products manufacturer v. law firm.** Plaintiff hired academics from a prominent university to develop technology related to new dental filling materials. After successful development of the new materials, defendant was hired to handle the USPTO filings to protect the technology. However, the law firm did not submit the required documentation timely, which resulted in a failure to obtain patent protection. Mr. Tregillis estimated the alleged damages to the plaintiff and performed the requisite market and company-specific analyses to support these opinions.
- **Royalty examinations.** Mr. Tregillis has led a number of royalty examinations, primarily in the entertainment and technology industries. These examinations have typically been performed for the licensor in evaluating amounts due and paid by licensees.
- **Spinal implant manufacturer v. spinal implant manufacturer.** Defendant was accused of infringing patents related to technology used in screws that lock vertebrae in place to encourage proper healing of degenerating elements of the spine. Mr. Tregillis analyzed lost profit and reasonable royalty damages issues, as adduced in an expert report per Rule 26 of the Federal Rules of Evidence; the matter later settled.
- **Ophthalmic technology licensing negotiation assistance.** A non-profit entity developed technology with applications in the ophthalmic field and intended to continue developing those technologies and other future pursuits. Mr. Tregillis financially analyzed the technology and terms of various forms of agreements, including the incremental monetary value of a variety of terms, as well as consideration of potential conflicting agreements that the developer had with multiple simultaneous license negotiations with various parties covering similar products.
- **US (relator) v. doctor group.** Defendants were alleged to have improperly billed the government for medical procedures that were alleged to have been "experimental" in nature. Mr. Tregillis and his team performed an accounting of reimbursements and monies paid to defendants for the procedures, as well as how the monies were distributed.
- **Real estate developer v. lender.** Plaintiff claimed that defendant's foreclosure on a loan was wrongful, primarily as a result of inaccurate documentation. Mr. Tregillis performed an investigation and testified at trial as to the accounting of the life of the loan, including a reorganization, as well as the foreclosure process and sale as elements of damages.



- **University medical center adv. cancer treatment company.** After jointly developing technology and a commercial infrastructure to support proton beam therapy treatment, the university agreed to assign ownership to the company and to license the technology as part of a contract for maintenance for the facility. Mr. Tregillis valued the intellectual property (patents and trade secrets) used by the facility in an attempt to negotiate a restructuring of the original agreement.
- **Medical products company adv. individual.** The company manufactures and distributes topical creams and treatments for mouth sores and executed a license agreement with the individual - a doctor who patented technology that is used in many of the company's products. The dispute related to amounts paid compared to amounts allegedly due, whether the contract had been breached, and damages. Mr. Tregillis wrote a report on damages and provided testimony via declaration.
- **Analysis for financial reporting of exposure on patent infringement claim.** Mr. Tregillis and his team were asked to value a claim against a company accused of patent infringement on technology related to a commercially successful birth control drug. Per SFAS 5, an accrual must be taken when a liability is measurable and likely, and Mr. Tregillis's analysis was used to aid in preparing the company's financial statements and to disclose to stakeholders the company's exposure.
- **Beverage company founder v. financier.** After signing an agreement to take plaintiff's new beverage product to market, defendant failed to fund the operation as called for in the agreement, which resulted in plaintiff reaching an agreement with another financier on inferior terms, with a lesser percentage maintained by the founder. The financier counterclaimed that he owned the trademarks, which he alleged were therefore infringed. Mr. Tregillis quantified damages, measured as lost profits and lost business value, and testified at trial in the Central District of California.
- **Contract manufacturer adv. wireless technology company.** Plaintiff was contracted by defendant to manufacture, to specifications provided by defendant, child locator GPS wristwatches. The parties disagreed as to whether the responsibility of the failure to manufacture the wristwatches was a result of poor manufacturing or poor design, which brought about a claim by the contract manufacturer for amounts due under the contract, and a claim by the wireless company for the lost profits resulting from the lost opportunity to sell the wristwatches and related profits from subscription fees. Mr. Tregillis served as the rebuttal damages expert for the contract manufacturer, and was to testify at trial until counsel was successful with its motion to exclude the testimony of the opposition's damages expert.
- **Individual v. lender.** Mr. Tregillis analyzed damages due in a usury case in which there had been several refinancings, which obfuscated the interest and principal paid by the borrower and resulting damage claim. At trial, Mr. Tregillis testified for defendant as to his accounting on the matter. The case was subsequently dismissed.



- ***Mortgage insurance company v. mortgage lender.*** The mortgage lender, one of the largest originators of loans in the US, placed its mortgage insurance with several carriers, including plaintiff. After receiving loan origination documentation from a number of sources, including brokers, the lender packaged the loans for securitization with major banks and investors. Subsequently, some of the loans that were securitized with an express representation of coverage went into default and the carrier notified the lender that the loans were not, in fact, covered. Mr. Tregillis and his team were called in to investigate what had caused the lapse in coverage and discovered a number of problems in the lender's origination process, and over an extended period of time provided consultation on quantification of the financial impact of the flawed processes (including the loans with each of the carriers), process improvement, reporting and systems and information flow management.
- ***Investigation of sub-prime loan servicer.*** Mr. Tregillis and his team were separately asked by a number of different investors and a mortgage insurance carrier to lead investigations into the performance of a large sub-prime loan servicer. The analysis included evaluation of claims raised by a group of borrowers, a review of servicing processes employed and compliance with reporting requirements. Several of the clients ended up severing relationships with the servicer.
- ***SEC investigation of investment manager.*** The SEC investigated the practice of "cross trades" between client accounts as executed by the investment manager. Mr. Tregillis analyzed the financial impact of the trades on the clients and on the market for the securities, as well as estimating the price at which the trades would have occurred on the open market. The report was provided to the SEC in the context of their investigation.
- ***Estate of musician v. former counsel for estate.*** The dispute related to the sale by the plaintiff, the musician's father as executor of the estate, of rights to his son's music, which has enjoyed continued commercial success since the artist's death in 1970. Defendant acted as counsel to plaintiff in the sale, even though defendant also indirectly owned the company that purchased the rights. Mr. Tregillis managed the forensic accounting to trace the flow and quantification of funds after the transaction, in addition to the valuation of the rights as of the date of sale.
- ***Media company adv. individuals.*** The media company entered into a joint venture to promote Latin American concerts and other events in the U.S., with defendant individuals selling their ownership rights in the company, but agreeing to continue in an exclusive managerial role. The media company terminated the individuals after discovering that they had engaged in allegedly competitive acts and the theft of trade secret information. Mr. Tregillis testified in deposition and arbitration as to damages, alter-ego issues regarding the relationship between the individuals and their new companies, and the implications of the perceived lack of internal controls at the company surrounding the co-presidents and their handling of concert revenue, cash management and self-dealing.



- ***Estate of musician v. record label.*** After the musician died in a plane crash, the label notified the artist's manager that future royalties were to be offset against past amounts due for artist promotion and other expenses, with a total amount due of several million dollars. Mr. Tregillis assisted as the forensic accountant for the artist's estate and manager in an attempt to arrive at the actual amount of expenses to be charged to the artist, as well as the actual amount of royalties paid. The matter settled under confidential terms.
- ***Contractor v. individual.*** After a dispute over the quality of work done by the contractor, defendant communicated in the press and in person to potential clients that plaintiff did poor quality work – even though the arbitration ruling had indicated otherwise. Mr. Tregillis quantified damages to the contractor related to the alleged libel and slander, and he testified at trial in the matter.
- ***Individual v. accounting firm.*** Mr. Tregillis testified in arbitration as to the methodologies employed in performing a forensic accounting investigation and valuation of a business, including its patent portfolio, trade secrets and know-how.
- ***Airport baggage/passenger screening company v. U.S. government.*** Plaintiff was in the business of baggage and passenger screening at airports, and was put out of this business by the creation of the Transportation Security Administration after the events of September 11, 2001. In a takings case before the U.S. Court of Federal Claims, Mr. Tregillis provided testimony on damages, measured as the value of the business that was lost, at deposition and trial.
- ***Spa manufacturer v. former owner of company.*** Plaintiff purchased the assets of defendant's spa manufacturing business, including the warranty servicing responsibilities on the installed base. The dispute related to the warranty charges passed on the defendant, which defendant refused to pay. Mr. Tregillis testified at trial as to the results of his testing on the accuracy of the bill and whether there was a statistical indication that plaintiff had paid more warranty claims than had previously been paid by defendant in similar circumstances.
- ***Individuals v. retailer of residential heating units.*** The dispute related to the sale by defendant of allegedly faulty and dangerous residential heating units. Mr. Tregillis's role was to perform a statistical inference in the computation of damages to replace all units ever sold, given limited data on sales. After Mr. Tregillis provided deposition testimony, his analysis and declaration were used by the magistrate and counsel from both sides to settle the case.
- ***Computer manufacturer v. monitor manufacturer.*** Plaintiff brought a claim related to an alleged epidemic failure of monitors that defendant manufactured for plaintiff's computer systems sold to the public. Mr. Tregillis statistically analyzed the warranty claims to determine whether threshold levels of claims were reached and whether there were other contributory factors that may have led to errors in the data as accumulated related to servicing of monitors that failed. Mr. Tregillis also analyzed damages under alternative scenarios on behalf of counsel for defendant.



EDUCATION AND CERTIFICATIONS

- Occidental College, A.B. Economics with Distinction
- University of Chicago Graduate School of Business, M.B.A. Finance and Accounting
- Certified Public Accountant, Licensed in California and Certified in Illinois
- Accredited in Business Valuation, American Institute of Certified Public Accountants

PROFESSIONAL ACTIVITIES & AFFILIATIONS

- California Society of Certified Public Accountants - Chair, Economic Damages Section and Member, Steering Committee for Litigation Sections
- American Institute of Certified Public Accountants - Chair, Economic Damages Task Force and Member, Forensic & Litigation Services Committee
- Licensing Executives Society

PUBLICATIONS, PRESENTATIONS & SPEAKING

- *Income Statement Analysis*. Practising Law Institute, *Basics of Accounting and Finance* (September, 1998).
- *The Use of Outside Accountants*. Practising Law Institute course *Basics of Accounting and Finance* (September, 1998) – instructor and chapter author, “Overview of Services Provided by CPAs.”
- *Evaluating IP Lost Profits: From Panduit to Grain Processing*. California Society of CPAs publication, *The Witness Chair* (Summer, 2001).
- *The Valuation of Trademarks*. American Intellectual Property Lawyers Association Annual Meeting (October, 2001).
- *The Valuation of Intellectual Property*. San Diego Institute of Intellectual Property Lawyers Association Meeting (April, 2002).
- *Issues to Consider in Evaluating a Reasonable Royalty*. American Institute of CPAs publication, *CPA Expert* (Summer, 2002).
- *IP Through the Life of Your Business*. The Phelps Group: IP Summit (July, 2002).
- *The Use of Multiple Regression in Commercial Litigation*. California Society of CPAs, Economic Damages Section Meeting (October, 2002).
- *Review of Valuation for Financial Reporting: Intangible Assets, Goodwill, and Impairment Analysis, SFAS 141 & 142* (by Michael J. Mard, et al.). American Institute of CPAs publication, *CPA Expert* (Winter 2003).
- *The Use of Surveys and Statistics in Litigation*. California Society of CPAs, *Advanced Business Litigation Institute* (May, 2003).
- *Current Issues in IP Litigation Damages*. California Society of CPAs, *Advanced Business Litigation Institute* (May, 2003).



- *The Role of the Financial Expert in Trade Secret Litigation*. California Society of CPAs, Economic Damages Section Meeting (July, 2003).
- *Notes and Numbers: Does the Data on Declining Music Sales "Sing" In an Age of Music Downloading?* Los Angeles County Bar Assoc., Music Section Meeting (December, 2003).
- *Peer to Peer File Sharing Suits: What's Next?* California Society of CPAs publication, *The Witness Chair* (Winter, 2004).
- *AICPA Statement on Standards for Business Valuation*. California Society of CPAs, Economic Damages Section Meeting (February, 2004).
- *Research on Current Issues in Economic Damages*. California Society of CPAs, Economic Damages Section Meeting (May, 2004).
- *Assessing and Proving Damages from Infringement, Program Moderator*. University of Southern California Intellectual Property Institute (May, 2004).
- *Daubert Case Law*. American Institute of CPAs, *Conference on Fraud and Litigation Services* (September, 2004).
- *Cost Shifting and Electronic Discovery: How Experts Can Help Clients Minimize Costs*. California Society of CPAs publication, *The Witness Chair*, with Rachel Laybourn (Fall 2004).
- *Valuation of Intellectual Property*. California State Bar Intellectual Property Law Section, *Intellectual Property Institute* (November, 2004).
- *From Qualifications to Unsupported Opinions: A Review of Motions to Exclude Financial Experts*. California Society of CPAs, Economic Damages Section Meeting (February, 2005).
- *Challenges for the Intellectual Property Damages Expert: Apportionment of Value, Multiple Patent Litigation, Price Erosion, and the Entire Market Value Rule*. California Society of CPAs, *Advanced Business Litigation Institute* (May, 2005).
- *You've Been Sued for Infringement – Now What?* University of Southern California Intellectual Property Institute (May, 2005).
- *Fraud Identification, Protection and Management, Financial Executives International*. Seattle Section meeting (September, 2005).
- *Spending Your IP Dollars Wisely in Foreign Markets*. AeA Oregon Section Meeting (December, 2005).
- *Differences Between Lost Profits and Diminution in Business Value as a Measure of Damages*. American Institute of CPAs publication, BV-FLS Section Update, with Michael Thompson (January, 2006).
- *Practice Aid on Damages in Intellectual Property Disputes* (contributor/editor). American Institute of CPAs publication (February, 2006).
- *The Top 10 Things About IP Every Technology Manager Needs to Know*. Mentor Graphics User2User Conference (May, 2006).
- *Financing Issues in Managing Intellectual Property Risk*. Risk & Insurance Management Society Meeting, Los Angeles Chapter (June, 2006).



- *Awards for Future Damages in Patent Infringement Cases after eBay v. MercExchange*. American Bar Association, IPL Newsletter (Summer, 2006, Volume 24, Issue 4).
- *The Forensic Accountant's Role in Claims of Alter-Ego, Successor Liability, and Fraudulent Transfers*. California Society of CPAs, Economic Damages Section Meeting (October, 2006).
- *The Financial Expert Post-eBay: The Four-Factor Test and Future Royalties*. Law Seminars International, Calculating and Proving Patent Damages (February, 2007).
- *Econometric Analysis and Multiple Regression*. Chapter in *Litigation Services Handbook: The Role of the Financial Expert, (Fourth Edition)*, with Dr. Mohan Rao, edited by Peter Frank, Michael Wagner and Roman Weil (February, 2007); also in the supplement to the third edition.
- *Patent Rights in the Post-eBay Era: What You Need to Survive*. University of Southern California Intellectual Property Institute (March, 2007).
- *Current Issues in Patent Damages*. IQPC, 3rd Patent Strategies (March, 2007).
- *Conducting Internal Corporate Investigations*. Association of Corporate Counsel of America, Southern California quarterly meeting (April, 2007).
- *Top 10 Reasons Why Financial Experts Get Excluded and What to Do About It*. American Institute of Certified Public Accountants National Conference on Fraud and Litigation Services (September, 2007).
- *Forensic Accounting Investigations and Valuation Analysis in an XBRL World*. 16th XBRL International Conference (December, 2007).
- *The CPA's Handbook on Fraud and Commercial Crime Prevention*. American Institute of Certified Public Accountants publication (lead author – 2008 update) (May, 2008).
- *Forensic Investigation of Financial Statement Fraud: Case Studies*. Florida Institute of Certified Public Accountants, Accounting and Business Expo (May, 2008).
- Quarterly section chair updates/articles on *Economic Damages* topics and *AICPA Updates*. California Society of CPAs publication, *The Witness Chair* (2006-2008).
- Research assistant in the publication of textbooks in Microeconomics, Macroeconomics and Econometrics.
- Instructor, the Conviser Duffy (Becker) CPA Review Course.

EXHIBIT 2

Exhibit 2
Line Items Where Net Invoice Amount is Above WAC
COG Pricing Method

Acct #	Acct Name	Item #	NDC	Description	Product Type	Doc Type	Pricing Method	Contract Name	Billing Date	Billing Document	Unit Price Charged	Bill Qty	Net Invoice Amount	Gross Invoice Amount	WAC	Discount
667971	ARROW PHARMACY 015	1431857	5417723	CENTRUM SILVER TAB 100	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296782015	\$ 8.91	3	\$ 26.73	\$ 27.26	\$26.46	
667971	ARROW PHARMACY 015	1474857	31868720	ROBITUS COUGH GEL 20	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296782015	\$ 4.21	3	\$ 12.63	\$ 12.88	\$12.51	
667971	ARROW PHARMACY 015	2713451	31861210	ROBITUS FLU SYRP BERRY 4OZ	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296782015	\$ 3.90	2	\$ 7.80	\$ 7.96	\$ 7.72	
667971	ARROW PHARMACY 015	3556545	31867012	ROBITUS MAX/STR 4OZ	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296782015	\$ 4.21	2	\$ 8.42	\$ 8.59	\$ 8.34	
667971	ARROW PHARMACY 015	1426469	31868512	ROBITUS-DM SYRP 4OZ	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296782015	\$ 3.90	2	\$ 7.80	\$ 7.96	\$ 7.72	
667971	ARROW PHARMACY 015	2748283	31868518	ROBITUS-DM SYRP 8OZ	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296782015	\$ 6.22	2	\$ 12.44	\$ 12.69	\$12.32	
668003	ARROW PHARMACY 018	1474857	31868720	ROBITUS COUGH GEL 20	OTC items, sundries	Invoice	COG	NULL	3/1/2007	7297210984	\$ 4.21	2	\$ 8.42	\$ 8.59	\$ 8.34	
668003	ARROW PHARMACY 018	2519361	NULL	LABEL SAME MED DIFF APPEARC 1 M	OTC items, sundries	Invoice	COG	NULL	3/1/2007	7297210986	\$ 3.39	1	\$ 3.39	\$ 3.46	\$ 2.80	
668211	ARROW PHARMACY 044	1965920	573016030	ADVIL CAPL 50	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296756366	\$ 4.95	2	\$ 9.90	\$ 10.10	\$ 9.80	
668211	ARROW PHARMACY 044	1379957	573016930	ADVIL LIQGEL 200MG 40	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296756366	\$ 5.20	1	\$ 5.20	\$ 5.30	\$ 5.15	
668211	ARROW PHARMACY 044	1733609	573015040	ADVIL TAB 100	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296756366	\$ 8.07	2	\$ 16.14	\$ 16.46	\$15.98	
668211	ARROW PHARMACY 044	1733583	573015030	ADVIL TAB 50	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296756366	\$ 4.95	2	\$ 9.90	\$ 10.10	\$ 9.80	
668211	ARROW PHARMACY 044	1159250	573262048	ALAVERT ORAL/DISIN TAB MINT 48	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296756366	\$ 19.90	1	\$ 19.90	\$ 20.30	\$19.70	
668211	ARROW PHARMACY 044	1731892	573022567	ANBESOL GEL M/STR 0.33OZ	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296756366	\$ 4.63	2	\$ 9.26	\$ 9.45	\$ 9.16	
668211	ARROW PHARMACY 044	1133800	573123821	DRISTAN COLD TAB 20	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296756366	\$ 3.88	1	\$ 3.88	\$ 3.96	\$ 3.84	
668211	ARROW PHARMACY 044	1354661	5250033	FIBERCON CAPL 625MG 90	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296756366	\$ 9.45	1	\$ 9.45	\$ 9.64	\$ 9.36	
668211	ARROW PHARMACY 044	2713832	NULL	NO RINSE SHAM 16OZ	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296756366	\$ 3.28	1	\$ 3.28	\$ 3.35	\$ 2.98	
668211	ARROW PHARMACY 044	1934819	573284010	PREPARATION H COOLING GL 0.9OZ	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296756366	\$ 4.58	2	\$ 9.16	\$ 9.34	\$ 9.06	
668211	ARROW PHARMACY 044	1627686	573287120	PREPARATION H OINT 2OZ	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296756366	\$ 7.50	1	\$ 7.50	\$ 7.65	\$ 7.43	
668211	ARROW PHARMACY 044	1937382	573283010	PREPARATION H+HYDRO CRM 0.9OZ	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296756366	\$ 4.36	1	\$ 4.36	\$ 4.45	\$ 4.32	
668211	ARROW PHARMACY 044	1278811	NULL	ROBITUS C/DRP HERB+HNY 20	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296756366	\$ 1.13	3	\$ 3.39	\$ 3.46	\$ 3.36	
668211	ARROW PHARMACY 044	2713295	NULL	ROBITUS SUNNY ORANGE DROPS 25	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296756366	\$ 1.13	3	\$ 3.39	\$ 3.46	\$ 3.36	
668270	ARROW PHARMACY 054	1967173	573016040	ADVIL CAPL 100	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296791685	\$ 8.07	3	\$ 24.21	\$ 24.69	\$23.97	
668270	ARROW PHARMACY 054	1379957	573016930	ADVIL LIQGEL 200MG 40	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296791685	\$ 5.20	3	\$ 15.60	\$ 15.91	\$15.45	
668270	ARROW PHARMACY 054	1133800	573123821	DRISTAN COLD TAB 20	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296791685	\$ 3.88	3	\$ 11.64	\$ 11.87	\$11.52	
668270	ARROW PHARMACY 054	3556545	31867012	ROBITUS MAX/STR 4OZ	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296791685	\$ 4.21	3	\$ 12.63	\$ 12.88	\$12.51	
668270	ARROW PHARMACY 054	1426469	31868512	ROBITUS-DM SYRP 4OZ	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296791685	\$ 3.90	4	\$ 15.60	\$ 15.91	\$15.44	
668407	ARROW PHARMACY 079	1794627	31861012	ROBITUS PED COUGH 4OZ	OTC items, sundries	Invoice	COG	NULL	3/1/2007	7297207125	\$ 3.90	3	\$ 11.70	\$ 11.93	\$11.58	
668226	ARROW SPECIALTY PHCY 047	1426469	31868512	ROBITUS-DM SYRP 4OZ	OTC items, sundries	Invoice	COG	NULL	3/1/2007	7297207267	\$ 3.90	4	\$ 15.60	\$ 15.91	\$15.44	
688898	FAMILYMEDS PHARMACY 750	2169498	5550919	CALTRATE 600+D TAB 60	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296756178	\$ 5.01	2	\$ 10.02	\$ 10.22	\$ 9.92	
688898	FAMILYMEDS PHARMACY 750	3236023	96070760	DRYSOL DAB-O-MATIC SOL 60ML	General Rx item	Invoice	COG	NULL	2/26/2007	7296756178	\$ 8.39	1	\$ 8.39	\$ 8.56	\$ 8.62	
688920	FAMILYMEDS PHARMACY 752	1732502	573021541	ANBESOL LIQ M/STR 0.41OZ	OTC items, sundries	Invoice	COG	NULL	3/1/2007	7297223837	\$ 4.63	2	\$ 9.26	\$ 9.45	\$ 9.16	
681267	FAMILYMEDS PHARMACY 805	1934819	573284010	PREPARATION H COOLING GL 0.9OZ	OTC items, sundries	Invoice	COG	NULL	3/1/2007	7297202859	\$ 4.58	1	\$ 4.58	\$ 4.67	\$ 4.53	
681267	FAMILYMEDS PHARMACY 805	1462001	573266024	ALAVERT ALLER&SIN D-1 2HR TB 24	OTC items, sundries	Invoice	COG	NULL	3/1/2007	7297203984	\$ 10.91	1	\$ 10.91	\$ 11.13	\$10.80	
687051	FAMILYMEDS PHARMACY 813	1988344	573021825	ANBESOL GEL REG/STR 0.25OZ	OTC items, sundries	Invoice	COG	NULL	3/1/2007	7297202866	\$ 4.04	3	\$ 12.12	\$ 12.36	\$12.00	
687051	FAMILYMEDS PHARMACY 813	1644087	NULL	HEAT PAD MOIST/DRY DIG CARA 72	OTC items, sundries	Invoice	COG	NULL	3/1/2007	7297202866	\$ 19.62	1	\$ 19.62	\$ 20.01	\$18.69	
687051	FAMILYMEDS PHARMACY 813	1426394	31862412	ROBITUS SYRP 100MG 4OZ	OTC items, sundries	Invoice	COG	NULL	3/1/2007	7297202866	\$ 3.90	1	\$ 3.90	\$ 3.98	\$ 3.86	
687051	FAMILYMEDS PHARMACY 813	2748291	31862418	ROBITUS SYRP 100MG 8OZ	OTC items, sundries	Invoice	COG	NULL	3/1/2007	7297202866	\$ 6.22	1	\$ 6.22	\$ 6.34	\$ 6.16	
687051	FAMILYMEDS PHARMACY 813	1426469	31868512	ROBITUS-DM SYRP 4OZ	OTC items, sundries	Invoice	COG	NULL	3/1/2007	7297202866	\$ 3.90	2	\$ 7.80	\$ 7.96	\$ 7.72	
688111	FAMILYMEDS PHARMACY 819	2169498	5550919	CALTRATE 600+D TAB 60	OTC items, sundries	Invoice	COG	NULL	3/1/2007	7297204668	\$ 5.01	1	\$ 5.01	\$ 5.11	\$ 4.96	
688111	FAMILYMEDS PHARMACY 819	1404235	NULL	DIMETAPP C&A PE 4OZ	OTC items, sundries	Invoice	COG	NULL	3/1/2007	7297204668	\$ 4.18	1	\$ 4.18	\$ 4.26	\$ 4.14	
688126	FAMILYMEDS PHARMACY 830	1630631	74312000770	N/B VIT B-100 TAB 770 50	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296675433	\$ 5.57	1	\$ 5.57	\$ 5.68	\$ 5.30	
575242	FAMILYMEDS PHCY 726	2497147	NULL	ROBITUS DM S/F COUGH SYRP 4OZ	OTC items, sundries	Invoice	COG	NULL	3/1/2007	7297148256	\$ 3.90	1	\$ 3.90	\$ 3.98	\$ 3.86	
575360	FAMILYMEDS PHCY 733	1438860	NULL	DIMETAPP COLD PE DROPS 0.5OZ	OTC items, sundries	Invoice	COG	NULL	3/1/2007	7297185746	\$ 4.18	1	\$ 4.18	\$ 4.26	\$ 4.14	
575360	FAMILYMEDS PHCY 733	2748283	31868518	ROBITUS-DM SYRP 8OZ	OTC items, sundries	Invoice	COG	NULL	3/1/2007	7297185746	\$ 6.22	1	\$ 6.22	\$ 6.34	\$ 6.16	
668192	ZZARROW PHARMACY 042 6/07	1731892	573022567	ANBESOL GEL M/STR 0.33OZ	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296781400	\$ 4.63	2	\$ 9.26	\$ 9.45	\$ 9.16	
668456	ZZARROW PHCY 024 6/07	1627686	573287120	PREPARATION H OINT 2OZ	OTC items, sundries	Invoice	COG	NULL	2/26/2007	7296772209	\$ 7.50	1	\$ 7.50	\$ 7.65	\$ 7.43	
689052	ZZFAMILYMEDS PHY 085 10/7	1339217	29600922	AMOXIL SUSP 250MG 150ML	General Rx item	Invoice	COG	NULL	3/1/2007	7297235534	\$ 2.31	6	\$ 13.86	\$ 14.14	\$13.50	

EXHIBIT 2

EXHIBIT 3

Exhibit 3
Contract Names For Which Contract
Pricing Method Was Used

Contract Name	Lines	Net Invoice
JPC NURSING HOME PRVDR	64	\$ 22,506.44
GERIMED LTC MAIN LEAD	20	\$ 10,958.06
AHC OPC	97	\$ 8,607.28
JOINT PURCHASING HMO	26	\$ 6,307.04
AHC RTL	50	\$ 5,406.07
013 CMT C01899-1 ROCHE	3	\$ 2,440.84
AHC SPH	2	\$ 878.47
NETWORK NET-RETAIL	22	\$ 684.54
JOINT PURCHASING HIV	4	\$ 461.34
006 CMT A00330-1 ELILILLY	1	\$ 332.52
JOINT PURCHASING HOSP	1	\$ 248.50
013 CMT 1000070586 BD	6	\$ 155.05
013 CMT 05707001 ROSS	1	\$ 101.16
01 3 CMT 1 000070586 BD	1	\$ 22.15
FAMILY MED FAMMED1 00 PAR	1	\$ 21.91
FAMILYMEDS CONTRACT LEAD	1	\$ 14.61
Sums	300	\$ 59,145.98

EXHIBIT 3

EXHIBIT 4

Exhibit 4

Line Items Where Net Invoice Amount is Above WAC

Contract Pricing Method

Acct #	Acct Name	Item #	NDC	Description	Product Type	Doc Type	Pricing Method	Contract Name	Billing Date	Billing Document	Unit Price Charged	Bill Qty	Net Invoice Amount	Gross Invoice Amount	WAC	Discount
668041	ARROW PHARMACY 021	1250406	66993071230	MIRTAZAP OD TB 45MG UD PRAS30@	General Rx item	Invoice	Contract	NETWORK NET-RETAIL	3/1/2007	7297218510	\$ 74.22	1	\$ 74.22	\$ 75.70	\$ 70.02	
668216	ARROW PHARMACY 045	1313881	24208029905	LOTEMAX OPH SUSP 0.5% B&L 5ML	General Rx item	Invoice	Contract	AHC OPC	3/1/2007	7297211087	\$ 35.71	2	\$ 71.42	\$ 72.85	\$ 71.34	
668226	ARROW SPECIALTY PHCY 047	1930205	781181810	FUROSEM TAB 20MG SAN 1 000@	General Rx item	Invoice	Contract	NETWORK NET-RETAIL	3/1/2007	7297208761	\$ 38.27	1	\$ 38.27	\$ 39.04	\$ 36.10	
669266	FAMILYMEDS LTC PHCY 81 .5	3541315	54353244	LORAZEP O/S CON 2MG ROX 30ML	Class 3N or 4 Narcot	Invoice	Contract	JPC NURSING HOME PRVDR	3/1/2007	7297200672	\$ 34.60	2	\$ 69.20	\$ 70.58	\$ 69.12	
688898	FAMILYMEDS PHARMACY 750	2422194	60258019201	TRINATE TAB CYP 1.00@	General Rx item	Invoice	Contract	NETWORK NET-RETAIL	2/26/2007	7296756178	\$ 14.83	1	\$ 14.83	\$ 15.13	\$ 13.99	
681242	FAMILYMEDS PHARMACY 802	2432565	49502069203	ACCUNE B INH SOL 0.63MG/3ML 25	General Rx item	Invoice	Contract	AHC OPC	3/1/2007	7297204577	\$ 37.48	1	\$ 37.48	\$ 38.23	\$ 37.44	
681242	FAMILYMEDS PHARMACY 802	2471126	310020130	ARIMIDEX TAB 1MG 30	General Rx item	Invoice	Contract	JOINT PURCHASING HMO	3/1/2007	7297204577	\$ 232.12	1	\$ 232.12	\$ 236.76	\$231.84	
681242	FAMILYMEDS PHARMACY 802	1210731	85173301	AVELOX TAB 400MG 30	General Rx item	Invoice	Contract	AHC OPC	3/1/2007	7297204577	\$ 294.62	1	\$ 294.62	\$ 300.51	\$293.94	
681242	FAMILYMEDS PHARMACY 802	1137520	85128801	NASONEX NASAL SPR 50MCG 1 7GM	General Rx item	Invoice	Contract	AHC OPC	3/1/2007	7297204577	\$ 73.32	3	\$ 219.96	\$ 224.36	\$219.57	
688126	FAMILYMEDS PHARMACY 830	1137520	85128801	NASONEX NASAL SPR 50MCG 1 7GM	General Rx item	Invoice	Contract	AHC OPC	3/1/2007	7297151162	\$ 73.32	1	\$ 73.32	\$ 74.79	\$ 73.19	
688159	FAMILYMEDS PHARMACY 833	1380005	49884094969	MEGACE ES O/S 625MG/5ML 50Z	General Rx item	Invoice	Contract	AHC OPC	3/1/2007	7297151007	\$ 429.06	1	\$ 429.06	\$ 437.64	\$428.00	
575292	FAMILYMEDS PHCY 728	NULL	243256549502069000	ACCUNE B INH SOL 0.63MG/3ML 25	General Rx item	Invoice	Contract	AHC OPC	3/1/2007	7297197125	\$ 37.48	2	\$ 74.96	\$ 76.46	\$ 74.88	
575317	FAMILYMEDS PHCY 729	NULL	270444385140101	FORADIL CAP 12MCG 60	General Rx item	Invoice	Contract	AHC OPC	3/1/2007	7297197076	\$ 98.25	1	\$ 98.25	\$ 100.22	\$ 98.05	
575317	FAMILYMEDS PHCY 729	1137520	85128801	NASONEX NASAL SPR 50MCG 17GM	General Rx item	Invoice	Contract	AHC OPC	3/1/2007	7297197076	\$ 73.32	1	\$ 73.32	\$ 74.79	\$ 73.19	
575345	FAMILYMEDS PHCY 732	1262401	310070530	CASODEX TAB 30	General Rx item	Invoice	Contract	JOINT PURCHASING HMO	3/1/2007	7297198135	\$ 416.55	1	\$ 416.55	\$ 424.88	\$415.81	
575345	FAMILYMEDS PHCY 732	2158020	54373063	PROPRAN SOL 40MG ROX 500ML	General Rx item	Invoice	Contract	AHC OPC	3/1/2007	7297198135	\$ 42.06	2	\$ 84.12	\$ 85.80	\$ 84.02	
451387	TOYOTA FAMILY PHCY #411	2203552	60258026801	GFN/PSE/DM 60/1200/60 CYP 100	General Rx item	Invoice	Contract	NETWORK NET-RETAIL	2/26/2007	7296694437	\$ 59.88	1	\$ 59.88	\$ 61.08	\$ 56.49	
695538	WORKSITE PHCY 401	2207280	310075290	CRESTOR TAB 20MG 90	General Rx item	Invoice	Contract	JOINT PURCHASING HOSP	3/1/2007	7297176856	\$ 248.50	1	\$ 248.50	\$ 253.47	\$248.18	
668192	ZZARROW PHARMACY 042 6/07	2471126	310020130	ARIMIDEX TAB 1 MG 30	General Rx item	Invoice	Contract	JOINT PURCHASING HMO	3/1/2007	7297211892	\$ 232.12	1	\$ 232.12	\$ 236.76	\$231.84	
688882	ZZFAMILYMEDS PHY 749 2/09	1360759	54415725	CODEINE SULF TAB 60MG ROX 100	Class 2 Narcotic	Invoice	Contract	AHC OPC	3/1/2007	7297192968	\$ 54.83	3	\$ 164.49	\$ 167.78	\$164.22	

EXHIBIT 4

EXHIBIT 5

Exhibit 5

Line Items That Are Billed on the Same Day Using Two Different Pricing Methods

Acct #	Acct Name	Item #	NDC	Description	Product Type	Doc Type	Pricing Method	Contract Name	Billing Date	Billing Document	Unit Price Charged	Bill Qty	Net Invoice Amount	Gross Invoice Amount	WAC	Discount
669252	FAMILYMEDS PHARMACY 081	3658788	74197314	VICODIN ES TAB 750MG RXPAC 100	Class 3 Narcotic cag	Invoice	COG	NULL	3/1/2007	7297200447	\$ 89.68	4	\$ 358.72	\$ 365.89	\$ 368.72	
695538	WORKSITE PHCY 401	2761807	74518213	SYNTHROID TB 0.075MG 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297176856	\$ 42.94	1	\$ 42.94	\$ 43.80	\$ 44.14	
695538	WORKSITE PHCY 401	2761807	74518213	SYNTHROID TB 0.075MG 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297176856	\$ 42.94	1	\$ 42.94	\$ 43.80	\$ 44.14	
695538	WORKSITE PHCY 401	2761807	74518213	SYNTHROID TB 0.075MG 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297176856	\$ 42.94	1	\$ 42.94	\$ 43.80	\$ 44.14	
681267	FAMILYMEDS PHARMACY 805	2761807	74518213	SYNTHROID TB 0.075MG 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297203984	\$ 42.94	1	\$ 42.94	\$ 43.80	\$ 44.14	
681267	FAMILYMEDS PHARMACY 805	2761807	74518213	SYNTHROID TB 0.075MG 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297203984	\$ 42.94	1	\$ 42.94	\$ 43.80	\$ 44.14	
681267	FAMILYMEDS PHARMACY 805	2761807	74518213	SYNTHROID TB 0.075MG 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297203984	\$ 42.94	1	\$ 42.94	\$ 43.80	\$ 44.14	
688159	FAMILYMEDS PHARMACY 833	2762854	74662413	SYNTHROID TAB 0.1 MG 1 00	General Rx item	Invoice	COG	NULL	3/1/2007	7297151007	\$ 43.99	1	\$ 43.99	\$ 44.87	\$ 45.22	
688159	FAMILYMEDS PHARMACY 833	2762854	74662413	SYNTHROID TAB 0.1 MG 1 00	General Rx item	Invoice	COG	NULL	3/1/2007	7297151007	\$ 43.99	1	\$ 43.99	\$ 44.87	\$ 45.22	
669266	FAMILYMEDS LTC PHCY 81.5	1994888	50474000148	KEPPRA ORAL SOL 1 00MG/ML 16OZ	General Rx item	Invoice	Contract	GERIMED LTC MAIN LEAD	3/1/2007	7297200668	\$ 232.19	1	\$ 232.19	\$ 236.83	\$ 232.20	
959201	ZZFAMILYMEDS PHY 758 2/09	1199553	52152021402	OXYCOD HCL TAB 1 5MG ACTA 1 00	Class 2 Narcotic	Invoice	Contract	JPC NURSING HOME PRVDR	2/26/2007	7296752361	\$ 30.71	3	\$ 92.13	\$ 93.97	\$ 133.89	
575317	FAMILYMEDS PHCY 729	1199843	52152021502	OXYCOD HCL TAB 30MG ACTA 100	Class 2 Narcotic	Invoice	Contract	AHC OPC	3/1/2007	7297196503	\$ 53.66	2	\$ 107.32	\$ 109.47	\$ 174.58	

Acct #	Acct Name	Item #	NDC	Description	Product Type	Doc Type	Pricing Method	Contract Name	Billing Date	Billing Document	Unit Price Charged	Bill Qty	Net Invoice Amount	Gross Invoice Amount	WAC	Discount
667903	ZZARROW PHARMACY 001 6/07	1486851	74197314	VICODIN ES TAB 750MG 100	Class 3 Narcotic cag	Invoice	Net Billed	NULL	3/1/2007	7297207337	\$ 94.92	1	\$ 94.92	\$ 96.82	\$ 94.92	
575360	FAMILYMEDS PHCY 733	1227420	74518213	SYNTHROID TB 0.075MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297185746	\$ 42.36	1	\$ 42.36	\$ 43.21	\$ 40.31	
669266	FAMILYMEDS LTC PHCY 81 .5	1227420	74518213	SYNTHROID TB 0.075MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297200668	\$ 42.36	1	\$ 42.36	\$ 43.21	\$ 40.31	
668261	ARROW PHARMACY 048	1227420	74518213	SYNTHROID TB 0.075MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297217052	\$ 42.36	1	\$ 42.36	\$ 43.21	\$ 40.31	
575360	FAMILYMEDS PHCY 733	1227420	74518213	SYNTHROID TB 0.075MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297185746	\$ 42.36	1	\$ 42.36	\$ 43.21	\$ 40.31	
669266	FAMILYMEDS LTC PHCY 81 .5	1227420	74518213	SYNTHROID TB 0.075MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297200668	\$ 42.36	1	\$ 42.36	\$ 43.21	\$ 40.31	
668261	ARROW PHARMACY 048	1227420	74518213	SYNTHROID TB 0.075MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297217052	\$ 42.36	1	\$ 42.36	\$ 43.21	\$ 40.31	
668216	ARROW PHARMACY 045	1227453	74662413	SYNTHROID TAB 0.1MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297211087	\$ 43.62	2	\$ 87.24	\$ 88.98	\$ 82.74	
668010	ARROW PHARMACY 020	1227453	74662413	SYNTHROID TAB 0.1MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297199835	\$ 43.62	1	\$ 43.62	\$ 44.49	\$ 41.37	
669268	FAMILYMEDS PHARMACY 801	1994888	50474000148	KEPPRA ORAL SOL 1 00MG/ML 16OZ	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297203882	\$ 232.20	1	\$ 232.20	\$ 236.84	\$ 232.20	
667903	ZZARROW PHARMACY 001 6/07	1199553	52152021402	OXYCOD HCL TAB 15MG ACTA 100	Class 2 Narcotic	Invoice	Net Billed	NULL	2/26/2007	7296772982	\$ 48.32	2	\$ 96.64	\$ 98.57	\$ 89.26	
667903	ZZARROW PHARMACY 001 6/07	1199843	52152021502	OXYCOD HCL TAB 30MG ACTA 100	Class 2 Narcotic	Invoice	Net Billed	NULL	3/1/2007	7297207336	\$ 94.50	2	\$ 189.00	\$ 192.78	\$ 174.58	

EXHIBIT 5

EXHIBIT 6

Exhibit 6
Line Items With Same Product and Same Day, but Different WAC

Acct #	Acct Name	Item #	NDC	Description	Product Type	Doc Type	Pricing Method	Contract Name	Billing Date	Billing Document	Unit Price Charged	Bill Qty	Net Invoice Amount	Gross Invoice Amount	WAC	Discount
689054	ZZFAMILYMEDS PHY 0876/07	3254760	45051360	TYLENOL+COD #3 TAB RXPAC 1 00	Class 3 Narcotic cag	Invoice	Net Billed	NULL	2/26/2007	7296785387	\$ 43.48	1	\$ 43.48	\$ 44.35	\$ 41.41	
689054	ZZFAMILYMEDS PHY 0876/07	3254760	45051360	TYLENOL+COD #3 TAB RXPAC 1 00	Class 3 Narcotic cag	Invoice	Net Billed	NULL	2/26/2007	7296785387	\$ 43.48	1	\$ 43.48	\$ 44.35	\$ 41.41	
681242	FAMILYMEDS PHARMACY 802	1343763	45051360	TYLENOL+COD #3 TAB 100	Class 3 Narcotic cag	Invoice	Net Billed	NULL	2/26/2007	7296778583	\$ 50.11	1	\$ 50.11	\$ 51.11	\$ 50.11	
668192	ZZARROW PHARMACY 042 6/07	1343763	45051360	TYLENOL+COD #3 TAB 1 00	Class 3 Narcotic cag	Invoice	Net Billed	NULL	2/26/2007	7296781407	\$ 50.11	1	\$ 50.11	\$ 51.11	\$ 50.11	
669252	FAMILYMEDS PHARMACY 081	3658788	74197314	VICODIN ES TAB 750MG RXPAC 100	Class 3 Narcotic cag	Invoice	COG	NULL	3/1/2007	7297200447	\$ 89.68	4	\$ 358.72	\$ 365.89	\$ 368.72	
667903	ZZARROW PHARMACY 001 6/07	1486851	74197314	VICODIN ES TAB 750MG 100	Class 3 Narcotic cag	Invoice	Net Billed	NULL	3/1/2007	7297207337	\$ 94.92	1	\$ 94.92	\$ 96.82	\$ 94.92	
667941	ZZARROW PHARMACY 002 6/07	2762938	74434113	SYNTHROID TAB .025MG 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297206674	\$ 35.17	2	\$ 70.34	\$ 71.75	\$ 70.34	
575360	FAMILYMEDS PHCY 733	1227305	74434113	SYNTHROID TB 0.025MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297185746	\$ 33.85	1	\$ 33.85	\$ 34.53	\$ 32.37	
575360	FAMILYMEDS PHCY 733	1227420	74518213	SYNTHROID TB 0.075MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297185746	\$ 42.36	1	\$ 42.36	\$ 43.21	\$ 40.31	
668261	ARROW PHARMACY 048	1227420	74518213	SYNTHROID TB 0.075MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297217052	\$ 42.36	1	\$ 42.36	\$ 43.21	\$ 40.31	
669266	FAMILYMEDS LTC PHCY 81 .5	1227420	74518213	SYNTHROID TB 0.075MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297200668	\$ 42.36	1	\$ 42.36	\$ 43.21	\$ 40.31	
575360	FAMILYMEDS PHCY 733	1227420	74518213	SYNTHROID TB 0.075MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297185746	\$ 42.36	1	\$ 42.36	\$ 43.21	\$ 40.31	
668261	ARROW PHARMACY 048	1227420	74518213	SYNTHROID TB 0.075MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297217052	\$ 42.36	1	\$ 42.36	\$ 43.21	\$ 40.31	
669266	FAMILYMEDS LTC PHCY 81 .5	1227420	74518213	SYNTHROID TB 0.075MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297200668	\$ 42.36	1	\$ 42.36	\$ 43.21	\$ 40.31	
681267	FAMILYMEDS PHARMACY 805	2761807	74518213	SYNTHROID TB 0.075MG 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297203984	\$ 42.94	1	\$ 42.94	\$ 43.80	\$ 44.14	
695538	WORKSITE PHCY 401	2761807	74518213	SYNTHROID TB 0.075MG 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297176856	\$ 42.94	1	\$ 42.94	\$ 43.80	\$ 44.14	
681267	FAMILYMEDS PHARMACY 805	2761807	74518213	SYNTHROID TB 0.075MG 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297203984	\$ 42.94	1	\$ 42.94	\$ 43.80	\$ 44.14	
695538	WORKSITE PHCY 401	2761807	74518213	SYNTHROID TB 0.075MG 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297176856	\$ 42.94	1	\$ 42.94	\$ 43.80	\$ 44.14	
681267	FAMILYMEDS PHARMACY 805	2761807	74518213	SYNTHROID TB 0.075MG 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297203984	\$ 42.94	1	\$ 42.94	\$ 43.80	\$ 44.14	
695538	WORKSITE PHCY 401	2761807	74518213	SYNTHROID TB 0.075MG 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297176856	\$ 42.94	1	\$ 42.94	\$ 43.80	\$ 44.14	
688159	FAMILYMEDS PHARMACY 833	2762854	74662413	SYNTHROID TAB 0.1 MG 1 00	General Rx item	Invoice	COG	NULL	3/1/2007	7297151007	\$ 43.99	1	\$ 43.99	\$ 44.87	\$ 45.22	
688159	FAMILYMEDS PHARMACY 833	2762854	74662413	SYNTHROID TAB 0.1 MG 1 00	General Rx item	Invoice	COG	NULL	3/1/2007	7297151007	\$ 43.99	1	\$ 43.99	\$ 44.87	\$ 45.22	
668010	ARROW PHARMACY 020	1227453	74662413	SYNTHROID TAB 0.1MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297199835	\$ 43.62	1	\$ 43.62	\$ 44.49	\$ 41.37	
668216	ARROW PHARMACY 045	1227453	74662413	SYNTHROID TAB 0.1MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297211087	\$ 43.62	2	\$ 87.24	\$ 88.98	\$ 82.74	
668096	ZZARROW PHARMACY 029 6/07	2482768	52604510001	LEVOXYL TAB 100MCG RXPAC 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297219647	\$ 33.49	1	\$ 33.49	\$ 34.16	\$ 34.42	
688240	FAMILYMEDS PHARMACY 745	2495117	52604510001	LEVOXYL TAB 1 00MCG 100	General Rx item	Invoice	Contract	AHC OPC	3/1/2007	7297223737	\$ 28.21	1	\$ 28.21	\$ 28.77	\$ 35.18	
575345	FAMILYMEDS PHCY 732	2495117	52604510001	LEVOXYL TAB 1 00MCG 100	General Rx item	Invoice	Contract	AHC OPC	3/1/2007	7297198135	\$ 28.21	1	\$ 28.21	\$ 28.77	\$ 35.18	
668096	ZZARROW PHARMACY 029 6/07	2482768	52604510001	LEVOXYL TAB 100MCG RXPAC 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297219647	\$ 33.49	1	\$ 33.49	\$ 34.16	\$ 34.42	
689849	FAMILYMEDS PHARMACY 820	1324706	60793013601	SKELAXIN TAB 800MG RXPAC 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297228724	\$ 246.99	1	\$ 246.99	\$ 251.93	\$ 253.87	
688111	FAMILYMEDS PHARMACY 819	1324730	60793013601	SKELAXIN TAB 800MG 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297204668	\$ 248.72	2	\$ 497.44	\$ 507.39	\$ 511.30	
575242	FAMILYMEDS PHCY 726	1324730	60793013601	SKELAXIN TAB 800MG 100	General Rx item	Invoice	Contract	AHC OPC	3/1/2007	7297148256	\$ 248.60	1	\$ 248.60	\$ 253.57	\$ 255.65	
668192	ZZARROW PHARMACY 042 6/07	1324730	60793013601	SKELAXIN TAB 800MG 100	General Rx item	Invoice	Contract	AHC OPC	3/1/2007	7297211892	\$ 248.60	1	\$ 248.60	\$ 253.57	\$ 255.65	
689849	FAMILYMEDS PHARMACY 820	1324706	60793013601	SKELAXIN TAB 800MG RXPAC 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297228724	\$ 246.99	1	\$ 246.99	\$ 251.93	\$ 253.87	
689849	FAMILYMEDS PHARMACY 820	1324706	60793013601	SKELAXIN TAB 800MG RXPAC 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297228724	\$ 246.99	1	\$ 246.99	\$ 251.93	\$ 253.87	

EXHIBIT 6

Exhibit 6
Line Items With Same Product and Same Day, but Different WAC

Acct #	Acct Name	Item #	NDC	Description	Product Type	Doc Type	Pricing Method	Contract Name	Billing Date	Billing Document	Unit Price Charged	Bill Qty	Net Invoice Amount	Gross Invoice Amount	WAC	Discount
681242	FAMILYMEDS PHARMACY 802	1343763	45051360	TYLENOL+COD #3 TAB 100	Class 3 Narcotic cag	Invoice	Net Billed	NULL	2/26/2007	7296778583	\$ 50.11	1	\$ 50.11	\$ 51.11	\$ 50.11	
668192	ZZARROW PHARMACY 042 6/07	1343763	45051360	TYLENOL+COD #3 TAB 1 00	Class 3 Narcotic cag	Invoice	Net Billed	NULL	2/26/2007	7296781407	\$ 50.11	1	\$ 50.11	\$ 51.11	\$ 50.11	
689054	ZZFAMILYMEDS PHY 0876/07	3254760	45051360	TYLENOL+COD #3 TAB RXPAC 1 00	Class 3 Narcotic cag	Invoice	Net Billed	NULL	2/26/2007	7296785387	\$ 43.48	1	\$ 43.48	\$ 44.35	\$ 41.41	
689054	ZZFAMILYMEDS PHY 0876/07	3254760	45051360	TYLENOL+COD #3 TAB RXPAC 1 00	Class 3 Narcotic cag	Invoice	Net Billed	NULL	2/26/2007	7296785387	\$ 43.48	1	\$ 43.48	\$ 44.35	\$ 41.41	
667903	ZZARROW PHARMACY 001 6/07	1486851	74197314	VICODIN ES TAB 750MG 100	Class 3 Narcotic cag	Invoice	Net Billed	NULL	3/1/2007	7297207337	\$ 94.92	1	\$ 94.92	\$ 96.82	\$ 94.92	
669252	FAMILYMEDS PHARMACY 081	3658788	74197314	VICODIN ES TAB 750MG RXPAC 100	Class 3 Narcotic cag	Invoice	COG	NULL	3/1/2007	7297200447	\$ 89.68	4	\$ 358.72	\$ 365.89	\$ 368.72	
575360	FAMILYMEDS PHCY 733	1227305	74434113	SYNTHROID TB 0.025MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297185746	\$ 33.85	1	\$ 33.85	\$ 34.53	\$ 32.37	
667941	ZZARROW PHARMACY 002 6/07	2762938	74434113	SYNTHROID TAB .025MG 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297206674	\$ 35.17	2	\$ 70.34	\$ 71.75	\$ 70.34	
681267	FAMILYMEDS PHARMACY 805	2761807	74518213	SYNTHROID TB 0.075MG 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297203984	\$ 42.94	1	\$ 42.94	\$ 43.80	\$ 44.14	
681267	FAMILYMEDS PHARMACY 805	2761807	74518213	SYNTHROID TB 0.075MG 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297203984	\$ 42.94	1	\$ 42.94	\$ 43.80	\$ 44.14	
681267	FAMILYMEDS PHARMACY 805	2761807	74518213	SYNTHROID TB 0.075MG 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297203984	\$ 42.94	1	\$ 42.94	\$ 43.80	\$ 44.14	
695538	WORKSITE PHCY 401	2761807	74518213	SYNTHROID TB 0.075MG 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297176856	\$ 42.94	1	\$ 42.94	\$ 43.80	\$ 44.14	
695538	WORKSITE PHCY 401	2761807	74518213	SYNTHROID TB 0.075MG 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297176856	\$ 42.94	1	\$ 42.94	\$ 43.80	\$ 44.14	
695538	WORKSITE PHCY 401	2761807	74518213	SYNTHROID TB 0.075MG 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297176856	\$ 42.94	1	\$ 42.94	\$ 43.80	\$ 44.14	
575360	FAMILYMEDS PHCY 733	1227420	74518213	SYNTHROID TB 0.075MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297185746	\$ 42.36	1	\$ 42.36	\$ 43.21	\$ 40.31	
575360	FAMILYMEDS PHCY 733	1227420	74518213	SYNTHROID TB 0.075MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297185746	\$ 42.36	1	\$ 42.36	\$ 43.21	\$ 40.31	
668261	ARROW PHARMACY 048	1227420	74518213	SYNTHROID TB 0.075MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297217052	\$ 42.36	1	\$ 42.36	\$ 43.21	\$ 40.31	
668261	ARROW PHARMACY 048	1227420	74518213	SYNTHROID TB 0.075MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297217052	\$ 42.36	1	\$ 42.36	\$ 43.21	\$ 40.31	
669266	FAMILYMEDS LTC PHCY 81 .5	1227420	74518213	SYNTHROID TB 0.075MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297200668	\$ 42.36	1	\$ 42.36	\$ 43.21	\$ 40.31	
669266	FAMILYMEDS LTC PHCY 81 .5	1227420	74518213	SYNTHROID TB 0.075MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297200668	\$ 42.36	1	\$ 42.36	\$ 43.21	\$ 40.31	
668010	ARROW PHARMACY 020	1227453	74662413	SYNTHROID TAB 0.1MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297199835	\$ 43.62	1	\$ 43.62	\$ 44.49	\$ 41.37	
668216	ARROW PHARMACY 045	1227453	74662413	SYNTHROID TAB 0.1MG RXPAC 100	General Rx item	Invoice	Net Billed	NULL	3/1/2007	7297211087	\$ 43.62	2	\$ 87.24	\$ 88.98	\$ 82.74	
688159	FAMILYMEDS PHARMACY 833	2762854	74662413	SYNTHROID TAB 0.1 MG 1 00	General Rx item	Invoice	COG	NULL	3/1/2007	7297151007	\$ 43.99	1	\$ 43.99	\$ 44.87	\$ 45.22	
688159	FAMILYMEDS PHARMACY 833	2762854	74662413	SYNTHROID TAB 0.1 MG 1 00	General Rx item	Invoice	COG	NULL	3/1/2007	7297151007	\$ 43.99	1	\$ 43.99	\$ 44.87	\$ 45.22	
688240	FAMILYMEDS PHARMACY 745	2495117	52604510001	LEVOXYL TAB 1 00MCG 100	General Rx item	Invoice	Contract	AHC OPC	3/1/2007	7297223737	\$ 28.21	1	\$ 28.21	\$ 28.77	\$ 35.18	
668096	ZZARROW PHARMACY 029 6/07	2482768	52604510001	LEVOXYL TAB 100MCG RXPAC 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297219647	\$ 33.49	1	\$ 33.49	\$ 34.16	\$ 34.42	
668096	ZZARROW PHARMACY 029 6/07	2482768	52604510001	LEVOXYL TAB 100MCG RXPAC 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297219647	\$ 33.49	1	\$ 33.49	\$ 34.16	\$ 34.42	
575345	FAMILYMEDS PHCY 732	2495117	52604510001	LEVOXYL TAB 1 00MCG 100	General Rx item	Invoice	Contract	AHC OPC	3/1/2007	7297198135	\$ 28.21	1	\$ 28.21	\$ 28.77	\$ 35.18	
688111	FAMILYMEDS PHARMACY 819	1324730	60793013601	SKELAXIN TAB 800MG 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297204668	\$ 248.72	2	\$ 497.44	\$ 507.39	\$ 511.30	
689849	FAMILYMEDS PHARMACY 820	1324706	60793013601	SKELAXIN TAB 800MG RXPAC 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297228724	\$ 246.99	1	\$ 246.99	\$ 251.93	\$ 253.87	
689849	FAMILYMEDS PHARMACY 820	1324706	60793013601	SKELAXIN TAB 800MG RXPAC 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297228724	\$ 246.99	1	\$ 246.99	\$ 251.93	\$ 253.87	
689849	FAMILYMEDS PHARMACY 820	1324706	60793013601	SKELAXIN TAB 800MG RXPAC 100	General Rx item	Invoice	COG	NULL	3/1/2007	7297228724	\$ 246.99	1	\$ 246.99	\$ 251.93	\$ 253.87	
575242	FAMILYMEDS PHCY 726	1324730	60793013601	SKELAXIN TAB 800MG 100	General Rx item	Invoice	Contract	AHC OPC	3/1/2007	7297148256	\$ 248.60	1	\$ 248.60	\$ 253.57	\$ 255.65	
668192	ZZARROW PHARMACY 042 6/07	1324730	60793013601	SKELAXIN TAB 800MG 100	General Rx item	Invoice	Contract	AHC OPC	3/1/2007	7297211892	\$ 248.60	1	\$ 248.60	\$ 253.57	\$ 255.65	

EXHIBIT 7

Exhibit 7
McKesson Statement Adjustments After 9/19/2007

Customer Number	Customer Name	Billing Date	Due Date	Receiver Number	Order Reference	Description	Gross Amount	PF1	Amount Net	PF2	Receivable Number
640740	FAMILYMEDS SPEC PHCY 314	9/21/2007	9/28/2007	8900303176	27623LTC01	Addbill INV	\$ 35.04	P	\$ 35.04	P	8900303176
681272	FAMILYMEDS PHARMACY 806	9/28/2007	10/5/2007	8900303910	C000083	Addbill INV	\$ 33.91	P	\$ 33.91	P	8900303910
575242	FAMILYMEDS PHCY 726	9/28/2007	10/5/2007	8900303909	C000083	Addbill INV	\$ 60.32	P	\$ 60.32	P	8900303909
667896	FAMILYMEDS PHARMACY 815	10/12/2007	10/19/2007	7319987137	7317016174	149Invoice	\$ 496.93	P	\$ 496.93	P	7319987137
668419	FAMILYMEDS PHARMACY 095	10/15/2007	10/22/2007	8900305066	75232052	Addbill INV	\$ 624.81	P	\$ 624.81	P	8900305066
848208	FAMILYMEDS RTV CREDITS	10/18/2007	10/25/2007	7320563510	555650007232	191Invoice	\$ 102.04	P	\$ 102.04	P	7320563510
681263	FAMILYMEDS PHARMACY 804	10/23/2007	10/23/2007	7321008802	TPC 93428905	149Credit	\$ (160.06)	P	\$ (160.06)	P	7321008802
848208	FAMILYMEDS RTV CREDITS	10/29/2007	10/29/2007	7321620254	555650007232	191Credit	\$ (100.00)	P	\$ (100.00)	P	7321620254
640740	FAMILYMEDS SPEC PHCY 314	10/30/2007	11/6/2007	8900307548	1960100014	Addbill INV	\$ 32.04	P	\$ 32.04	P	8900307548
640740	FAMILYMEDS SPEC PHCY 314	11/6/2007	11/6/2007	7322482448	MCFS PR CORR CR	Pricing Cor	\$ (2,252.50)	P	\$ (2,252.50)	P	7322482448
640740	FAMILYMEDS SPEC PHCY 314	11/6/2007	11/6/2007	7322482449	MCFS PR CORR CR	Pricing Cor	\$ (294.57)	P	\$ (294.57)	P	7322482449
640740	FAMILYMEDS SPEC PHCY 314	11/6/2007	11/6/2007	7322482450	MCFS PR CORR CR	Pricing Cor	\$ (2,792.44)	P	\$ (2,792.44)	P	7322482450
640740	FAMILYMEDS SPEC PHCY 314	11/6/2007	11/6/2007	7322482451	MCFS PR CORR CR	Pricing Cor	\$ (3,603.96)	P	\$ (3,603.96)	P	7322482451
640740	FAMILYMEDS SPEC PHCY 314	11/6/2007	11/6/2007	7322482452	MCFS PR CORR CR	Pricing Cor	\$ (1,182.51)	P	\$ (1,182.51)	P	7322482452
640740	FAMILYMEDS SPEC PHCY 314	11/6/2007	11/6/2007	7322482453	MCFS PR CORR CR	Pricing Cor	\$ (485.08)	P	\$ (485.08)	P	7322482453
640740	FAMILYMEDS SPEC PHCY 314	11/6/2007	11/6/2007	7322482454	MCFS PR CORR CR	Pricing Cor	\$ (6,000.80)	P	\$ (6,000.80)	P	7322482454
640740	FAMILYMEDS SPEC PHCY 314	11/6/2007	11/13/2007	7322482455	MCFS PR CORR IN	Pricing Cor	\$ 2,262.09	P	\$ 2,262.09	P	7322482455
640740	FAMILYMEDS SPEC PHCY 314	11/6/2007	11/13/2007	7322482456	MCFS PR CORR IN	Pricing Cor	\$ 295.81	P	\$ 295.81	P	7322482456
640740	FAMILYMEDS SPEC PHCY 314	11/6/2007	11/13/2007	7322482457	MCFS PR CORR IN	Pricing Cor	\$ 2,804.43	P	\$ 2,804.43	P	7322482457
640740	FAMILYMEDS SPEC PHCY 314	11/6/2007	11/13/2007	7322482458	MCFS PR CORR IN	Pricing Cor	\$ 3,619.35	P	\$ 3,619.35	P	7322482458
640740	FAMILYMEDS SPEC PHCY 314	11/6/2007	11/13/2007	7322482459	MCFS PR CORR IN	Pricing Cor	\$ 1,187.57	P	\$ 1,187.57	P	7322482459
640740	FAMILYMEDS SPEC PHCY 314	11/6/2007	11/13/2007	7322482460	MCFS PR CORR IN	Pricing Cor	\$ 487.14	P	\$ 487.14	P	7322482460
640740	FAMILYMEDS SPEC PHCY 314	11/6/2007	11/13/2007	7322482461	MCFS PR CORR IN	Pricing Cor	\$ 6,026.43	P	\$ 6,026.43	P	7322482461
640740	FAMILYMEDS SPEC PHCY 314	11/8/2007	11/8/2007	7322767686	MCFS PR CORR CR	Pricing Cor	\$ (13,116.20)	P	\$ (13,116.20)	P	7322767686
640740	FAMILYMEDS SPEC PHCY 314	11/8/2007	11/15/2007	7322767687	MCFS PR CORR IN	Pricing Cor	\$ 13,172.20	P	\$ 13,172.20	P	7322767687
695538	WORKSITE PHCY 401	12/3/2007	12/10/2007	8900311166	C000083	Addbill INV	\$ 8.12	P	\$ 8.12	P	8900311166
681263	FAMILYMEDS PHARMACY 804	12/6/2007	12/6/2007	7325593919	TPC 90814732	149Credit	\$ (1,071.78)	P	\$ (1,071.78)	P	7325593919
689849	FAMILYMEDS PHARMACY 820	12/7/2007	12/7/2007	7325736321	TPC 9700036940	149Credit	\$ (113.70)	P	\$ (113.70)	P	7325736321
668185	ARROW PHARMACY 040	12/7/2007	12/7/2007	7325738532	TPC 9700036919	191Credit	\$ (238.43)	P	\$ (238.43)	P	7325738532
668185	ARROW PHARMACY 040	12/10/2007	12/10/2007	7325899344	TPC 970036926	191Credit	\$ (117.77)	P	\$ (117.77)	P	7325899344
668010	ARROW PHARMACY 020	1/9/2008	1/9/2008	7328855591	TPC 93139876	191Credit	\$ (68.75)	P	\$ (68.75)	P	7328855591
640740	FAMILYMEDS SPEC PHCY 314	1/10/2008	1/17/2008	8900315489	GERI0908	Addbill INV	\$ 7.92	P	\$ 7.92	P	8900315489
688110	FAMILYMEDS PHARMACY 818	1/11/2008	1/18/2008	8900315910	27623ATA01	Addbill INV	\$ 9.14	P	\$ 9.14	P	8900315910
640740	FAMILYMEDS SPEC PHCY 314	2/1/2008	2/8/2008	8900322003	ARM0610	Addbill INV	\$ 20.88	P	\$ 20.88	P	8900322003
780285	ZZVALLEY DRUG COMPANY SOU	2/14/2008	2/21/2008	7332809761	Unreturned Telxo	115Invoice	\$ 255.10	P	\$ 255.10	P	7332809761
781045	FAMILYMEDS SPEC PHCY SVCS	2/25/2008	2/25/2008	7333890880	TPC 2600484952	191Credit	\$ (1,260.57)	P	\$ (1,260.57)	P	7333890880
780285	ZZVALLEY DRUG COMPANY SOU	3/25/2008	4/1/2008	7337098823	7337098823	Fee Billing	\$ 500.00	P	\$ 500.00	P	7337098823
668419	FAMILYMEDS PHARMACY 095	4/7/2008	4/7/2008	7338474537	MCFS PR CORR CR	Pricing Cor	\$ (5.28)	P	\$ (5.28)	P	7338474537
668419	FAMILYMEDS PHARMACY 095	4/7/2008	4/14/2008	7338474538	MCFS PR CORR IN	Pricing Cor	\$ 4.54	P	\$ 4.54	P	7338474538
668185	ARROW PHARMACY 040	5/2/2008	5/2/2008	7341375018	TPC 92469633	191Credit	\$ (112.90)	P	\$ (112.90)	P	7341375018
668261	ARROW PHARMACY 048	5/30/2008	5/30/2008	7344390088	TPC 319283	191Credit	\$ (2,655.63)	P	\$ (2,655.63)	P	7344390088

EXHIBIT 7

EXHIBIT 8

Exhibit 8
Customers with Negative Balances

Customer Number	Customer Name	Net Invoice Amount
668003	ARROW PHARMACY 018	\$ (3,740.85)
681263	FAMILYMEDS PHARMACY 804	\$ (5,445.29)
681267	FAMILYMEDS PHARMACY 805	\$ (4,463.50)
667896	FAMILYMEDS PHARMACY 815	\$ (6,814.07)
603805	FAMILYMEDS PHCY	\$ (15,022.05)
781045	FAMILYMEDS SPEC PHCY SVCS	\$ (1,191.67)
Sum		\$ (36,677.43)

Inappropriately Assessed Late Fees \$ (6,235.16)

EXHIBIT 8

EXHIBIT 9

Exhibit 9
Selected Past Due Service Charges Of Unusual Amounts

Customer Number	Customer Name	Billing Date	Due Date	Earliest Invoice Due Date	Latest Invoice Due Date	Days After Early Due Date	Days After Late Due Date	Outstanding Past Due Invoice Amount	Order Reference	Description	Past Due Charge	% of Invoiced Amount
575360	FAMILYMEDS PHCY 733	09/17/07	09/24/07	03/05/07	03/08/07	196	193	\$ 10,743.06	Service Chg	PastDueBal	\$166.30	1.55%
667858	FAMILYMEDS PHARMACY 811	09/17/07	09/24/07	03/05/07	03/08/07	196	193	\$ 7,424.62	Service Chg	PastDueBal	\$139.12	1.87%
667941	ZZARROW PHARMACY 002 6/07	09/17/07	09/24/07	03/05/07	03/08/07	196	193	\$ 9,308.63	Service Chg	PastDueBal	\$138.54	1.49%
668003	ARROW PHARMACY 018	09/17/07	09/24/07	03/05/07	03/08/07	196	193	\$ (3,788.66)	Service Chg	PastDueBal	\$ 47.81	-1.26%
668108	ZZARROW PHARMACY 036 6/07	09/17/07	09/24/07	03/05/07	03/08/07	196	193	\$ 8,836.32	Service Chg	PastDueBal	\$152.93	1.73%
668185	ARROW PHARMACY 040	09/17/07	09/24/07	03/05/07	03/08/07	196	193	\$ 10,678.33	Service Chg	PastDueBal	\$142.15	1.33%
668192	ZZARROW PHARMACY 042 6/07	09/17/07	09/24/07	03/05/07	03/08/07	196	193	\$ 6,594.71	Service Chg	PastDueBal	\$122.98	1.86%
668211	ARROW PHARMACY 044	09/17/07	09/24/07	03/05/07	04/07/07	196	163	\$ 12,941.55	Service Chg	PastDueBal	\$176.86	1.37%
668216	ARROW PHARMACY 045	09/17/07	09/24/07	03/05/07	03/08/07	196	193	\$ 8,852.44	Service Chg	PastDueBal	\$128.41	1.45%
668399	ZZARROW PHCY 078 6/07	09/17/07	09/24/07	03/05/07	03/08/07	196	193	\$ 7,268.10	Service Chg	PastDueBal	\$113.56	1.56%
668463	FAMILYMEDS PHARMACY 825	09/17/07	09/24/07	03/05/07	03/08/07	196	193	\$ 7,647.50	Service Chg	PastDueBal	\$125.07	1.64%
669202	FAMILYMEDS PHARMACY 073	09/17/07	09/24/07	03/05/07	03/08/07	196	193	\$ 6,405.28	Service Chg	PastDueBal	\$113.45	1.77%
687052	FAMILYMEDS PHARMACY 816	09/17/07	09/24/07	03/05/07	03/08/07	196	193	\$ 11,280.65	Service Chg	PastDueBal	\$179.14	1.59%
688240	FAMILYMEDS PHARMACY 745	09/17/07	09/24/07	03/08/07	03/08/07	193	193	\$ 3,878.26	Service Chg	PastDueBal	\$ 96.25	2.48%
688292	FAMILYMEDS PHARMACY 746	09/17/07	09/24/07	03/05/07	03/08/07	196	193	\$ 6,517.64	Service Chg	PastDueBal	\$114.82	1.76%
688807	FAMILYMEDS PHARMACY 747	09/17/07	09/24/07	03/05/07	03/08/07	196	193	\$ 6,787.55	Service Chg	PastDueBal	\$108.53	1.60%
688882	ZZFAMILYMEDS PHY 749 2/09	09/17/07	09/24/07	03/05/07	03/08/07	196	193	\$ 11,694.97	Service Chg	PastDueBal	\$162.32	1.39%
689056	ZZFAMILYMEDS PHY 088 10/7	09/17/07	09/24/07	03/05/07	03/08/07	196	193	\$ 8,691.00	Service Chg	PastDueBal	\$134.53	1.55%
689848	FAMILYMEDS PHARMACY 810	09/17/07	09/24/07	03/05/07	03/08/07	196	193	\$ 8,480.35	Service Chg	PastDueBal	\$127.28	1.50%

EXHIBIT 9